Republicans debate ahead of runoff for Alabama congressional seat
MONTGOMERY, Ala. (AP) — The two Republicans running for Alabama’s redrawn 2nd Congressional District clashed in a debate that aired Monday ahead of next week’s runoff.
Dick Brewbaker, a businessman and former state senator, and Caroleene Dobson, an attorney and political newcomer, are vying for the GOP nomination in the April 16 runoff. The winner will face the Democratic nominee in the closely watched November election.
Dobson and Brewbaker traded verbal jabs in the debate as Dobson criticized legislative votes that Brewbaker had taken on taxes and business regulation. Brewbaker fired back that Dobson was repeatedly lying about his record.
“We don’t need to send a retired career politician,” Dobson said in her opening statement. “If you send me, I’ll stand tall with President Trump against the left.”
Brewmaker said, “everything she has ever said about my record” has been a distortion. “As a car dealer, believe me, I know a lot more about the effect of regulation on small business than a lawyer from Texas.”
Related articles
Spanish city of Barcelona celebrates day of books and love
Thousands of people were on the streets of the northeastern Spanish city of Barcelona on Tuesday for2024-04-30Posts misrepresent a photo of a Ukrainian soldier balancing on his prosthetic limbs
CLAIM: A photo shows a Ukrainian soldier from the Azov Regiment who lost both legs and his left arm2024-04-30Nearly half of the world’s migratory species are in decline, UN report says
WASHINGTON (AP) — Nearly half of the world’s migratory species are in decline, according to a new Un2024-04-30Coalition's first budget to be unveiled on 30 May
Finance Minister Nicola Willis says the government is focusing on putting more money in people's poc2024-04-30The North London neighbourhood plagued by anti
Shocking CCTV showing the 'attempted kidnap' of a Jewish man in Stamford Hill will renew fears the a2024-04-30Study: Many cancer drugs unproven 5 years after accelerated approval
The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early2024-04-30
atest comment